1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
BioNexus Gene Lab's 1-Year ROIIC % for the quarter that ended in Mar. 2024 was 213.47%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for BioNexus Gene Lab's 1-Year ROIIC % or its related term are showing as below:
BGLC's 1-Year ROIIC % is ranked better than 92.38% of 1351
companies
in the Chemicals industry
Industry Median: 0.08
vs BGLC: 213.47
BioNexus Gene Lab 1-Year ROIIC % Historical Data
The historical data trend for BioNexus Gene Lab's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioNexus Gene Lab's 1-Year ROIIC %
For the Specialty Chemicals subindustry, BioNexus Gene Lab's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab's 1-Year ROIIC % Distribution in the Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's 1-Year ROIIC % falls into.
BioNexus Gene Lab 1-Year ROIIC % Calculation
BioNexus Gene Lab's 1-Year ROIIC % for the quarter that ended in Mar. 2024 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -2.645 (Mar. 2024) - -0.4292 (Mar. 2023) )
/
( 3.645 (Mar. 2024) - 4.683 (Mar. 2023) )
=
-2.2158
/
-1.038
=
213.47%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
BioNexus Gene Lab 1-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of BioNexus Gene Lab's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
BioNexus Gene Lab (BioNexus Gene Lab) Business Description
BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BGLC has been successfully added to your 